Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
The companies plan to use the proceeds to retire debt and expand operations
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
Equity raise to finance growth and investments in the biological space
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
It strengthens its presence to over 250 stores
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
Subscribe To Our Newsletter & Stay Updated
